Ipsen S.A. (IPSEF)
OTCMKTS · Delayed Price · Currency is USD
113.13
+9.63 (9.30%)
At close: Jun 9, 2025
Ipsen Employees
Ipsen had 5,358 employees as of December 31, 2024. The number of employees increased by 33 or 0.62% compared to the previous year.
Employees
5,358
Change (1Y)
33
Growth (1Y)
0.62%
Revenue / Employee
$824,095
Profits / Employee
$98,173
Market Cap
11.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,358 | 33 | 0.62% |
| Dec 31, 2023 | 5,325 | 253 | 4.99% |
| Dec 31, 2022 | 5,072 | -672 | -11.70% |
| Dec 31, 2021 | 5,744 | 41 | 0.72% |
| Dec 31, 2020 | 5,703 | -104 | -1.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
Ipsen News
- 11 days ago - Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy - Nasdaq
- 6 weeks ago - Ipsen Secures Japanese Approval For Bylvay In Treating Pruritus - Nasdaq
- 7 weeks ago - Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome - Benzinga
- 2 months ago - Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) - GlobeNewsWire
- 3 months ago - Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors - Seeking Alpha
- 4 months ago - Madrigal, Ipsen, SpringWorks get EU backing for their drugs - Seeking Alpha